Bon Natural Life Swings to $9.2M Net Loss on Credit Losses and Supplier Impairments
BON sits 21% above its 52-week low of $0.984.
Summary
Bon Natural Life swung to a $9.2M net loss in H1 2026, driven by $5.7M in credit loss provisions and $1.9M in supplier advance impairments, despite modest revenue growth.
Key Events · Earnings and Guidance · BON
-
Net Loss of $9.2M
Net loss attributable to Bon Natural Life was $9,201,131 for H1 2026, versus net income of $169,227 in H1 2025 — a swing of $9.4 million.
-
Credit Loss Provision
The company recorded a $5,656,888 provision for credit losses under CECL, including $2,566,939 against accounts receivable and $3,089,949 against other receivables.
-
Supplier Advance Impairment
Impairment losses on advances to suppliers totaled $1,920,508, with no comparable charge in H1 2025.
-
Revenue Growth Stalls
Total revenue rose only 1.9% to $8,097,810, as a 60.4% drop in fragrance compound sales offset strong growth in health supplements and bioactive food ingredients.
Analysis · BON · Life Sciences
A $9.2 million net loss for the six months ended March 31, 2026, replaced a $169,227 profit a year earlier. The swing was driven almost entirely by non-cash charges: a $5.7 million provision for credit losses and a $1.9 million impairment on advances to suppliers. Revenue grew only 1.9% to $8.1 million, while operating expenses ballooned to $10.8 million from $1.6 million. The company still holds $9.2 million in cash, but the deterioration in receivables and supplier advances raises questions about the quality of its balance sheet and the collectability of its working capital.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 36.1% of the 1052 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.56%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, BON was trading at $1.20 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $9.7M. The 52-week trading range was $0.98 to $2.34. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.